I've been wanting to bring up DNA sequencing for a while. This was just a research technology for a long time but covid officially changed that - people speculated about personalized medicine blah blah blah for a decade. But once we started sequencing covid samples on an unprecedented scale to identify variants, those speculations became irrelevant. DNA sequencing is now health care.
There are two major companies worth watching here from the perspective of the technology. Illumina (ILMN) has the DNA sequencing market locked down currently, this is by far the leading tech. It beat all the older platforms and its what everyone does now, for the most part.
Nanopore (ONTTF) looked like another promising tech that would go nowhere for many years. But its here now, fully in production mode, and beats Illumina in several important ways.
- Read length - Illumina can only read short DNA sequences which then have to be pieced back together computationally. (This is not always accurate or even possible). Nanopore reads are so long they can read entire Bacterial chromosomes or genomes.
- Instrument cost - all previous DNA sequencing technologies required expensive instruments (100k-1M). Only major sequencing centers could afford these. The Nanopore "MinION", the first truly third-generation sequencing technology, costs $1k. Individual labs are buying these. I bought one myself (havent had time to do any work with it yet to be honest). This massively expands the market for sequencing.
The DNA sequencing industry works on the same model as printers - you have to buy the consumables from the manufacturer; thats where they make their money. The advent of $1k sequencers with the huge expansion of buyers (individual labs instead of universities) means they're setting themselves up to sell a whole lot of consumables.
ILMN trades at $349 and doesnt look like its done terribly well as an investment over the past year. ONTTF trades at <$5 if you can find a way to buy it -- currently neither Fidelity or Wells Fargo offer trades on this stock.
Purely based on the tech, this company *should* steal a whole bunch of the DNA sequencing market (not all, since Illumina does offer some technical advantages for some applications). I'll buy some when it can be bought again.
But even from a noob perspective its clear ONTTF is struggling as a company compared with ILMN. If any investors want to look into these companies I'd be curious to hear your takes on the financial side.